

Alan P Venook

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2274462/publications.pdf>

Version: 2024-02-01

63
papers

4,587
citations

201674

27
h-index

133252

59
g-index

65
all docs

65
docs citations

65
times ranked

7489
citing authors

#	ARTICLE	IF	CITATIONS
1	Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405. <i>Journal of the National Cancer Institute</i> , 2022, 114, 427-435.	6.3	24
2	Feasibility and Acceptability of a Physical Activity Tracker and Text Messages to Promote Physical Activity During Chemotherapy for Colorectal Cancer: Pilot Randomized Controlled Trial (Smart Pace) Tj ETQq0 0 0 rBT /Overlock 10 Tf 5	2.8	6
3	Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer 70 years. <i>European Journal of Cancer</i> , 2022, 163, 1-15.	2.8	6
4	Quality of life of colorectal cancer survivors participating in a pilot randomized controlled trial of physical activity trackers and daily text messages. <i>Supportive Care in Cancer</i> , 2022, 30, 4557-4564.	2.2	7
5	Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance). <i>Clinical Cancer Research</i> , 2022, 28, 2779-2788.	7.0	11
6	Tumor Immunogenomic Features Determine Outcomes in Patients with Metastatic Colorectal Cancer Treated with Standard-of-Care Combinations of Bevacizumab and Cetuximab. <i>Clinical Cancer Research</i> , 2022, 28, 1690-1700.	7.0	7
7	IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa074.	2.9	6
8	Clinical Validation of a Machine-learning-derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1174-1183.	7.0	28
9	Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance). <i>Clinical Cancer Research</i> , 2021, 27, 267-275.	7.0	13
10	Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110205.	3.2	3
11	<i>BRAF</i> V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1386-1395.	6.3	17
12	Race, Income, and Survival in Stage III Colon Cancer: CALGB 89803 (Alliance). <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab034.	2.9	4
13	Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1705-1713.	6.3	12
14	Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance). <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz078.	2.9	22
15	Heated Intraperitoneal Chemotherapy for Colorectal Carcinomatosis: Emerging Evidence. <i>Clinical Colorectal Cancer</i> , 2020, 19, 1-4.	2.3	1
16	Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa024.	2.9	8
17	Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2020, 6, 1713.	7.1	24
18	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal Anal Task Forces whitepaper. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 757-770.	27.6	218

#	ARTICLE	IF	CITATIONS
19	Clinicopathologic Characteristics and Impact of Oophorectomy for Ovarian Metastases from Colorectal Cancer. <i>Oncologist</i> , 2020, 25, 564-571.	3.7	14
20	Feasibility and Acceptability of a Web-Based Dietary Intervention with Text Messages for Colorectal Cancer: A Randomized Pilot Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 752-760.	2.5	15
21	Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405. <i>Journal of Clinical Oncology</i> , 2019, 37, 2620-2631.	1.6	51
22	Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance). <i>Clinical Cancer Research</i> , 2019, 25, 7497-7505.	7.0	44
23	Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance). <i>Journal of Clinical Oncology</i> , 2019, 37, 1876-1885.	1.6	169
24	Self-monitoring and reminder text messages to increase physical activity in colorectal cancer survivors (Smart Pace): a pilot randomized controlled trial. <i>BMC Cancer</i> , 2019, 19, 218.	2.6	66
25	Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome. <i>Journal of Clinical Oncology</i> , 2019, 37, 1217-1227.	1.6	234
26	RasGRP1 is a potential biomarker for stratifying anti-EGFR therapy response in colorectal cancer. <i>JCI Insight</i> , 2019, 4, .	5.0	17
27	NCCN Guidelines Insights: Colon Cancer, Version 2.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 359-369.	4.9	675
28	Association of Survival With Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis. <i>JAMA Oncology</i> , 2018, 4, 783.	7.1	147
29	Of Microbes and Microsatellites. <i>Cancer Immunology Research</i> , 2018, 6, 1290-1291.	3.4	0
30	A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2702-2709.	4.1	30
31	Being Present: A single-arm feasibility study of audio-based mindfulness meditation for colorectal cancer patients and caregivers. <i>PLoS ONE</i> , 2018, 13, e0199423.	2.5	29
32	Identification of a Genomic Region between <i>SLC29A1</i> and <i>HSP90AB1</i> Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). <i>Clinical Cancer Research</i> , 2018, 24, 4734-4744.	7.0	14
33	Reply to L. Casadaban et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 1373-1374.	1.6	0
34	Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. <i>JAMA Oncology</i> , 2017, 3, 1043.	7.1	98
35	Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2392.	7.4	670
36	Differences in symptom occurrence, severity, and distress ratings between patients with gastrointestinal cancers who received chemotherapy alone or chemotherapy with targeted therapy. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 109-126.	1.4	19

#	ARTICLE	IF	CITATIONS
37	Radioembolization with 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 860-874.	1.4	27
38	Differential Radiographic Appearance of BRAF V600E Mutant Metastatic Colorectal Cancer in Patients Matched by Primary Tumor Location. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1536-1543.	4.9	17
39	Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). <i>Cancer Medicine</i> , 2016, 5, 2249-2260.	2.8	19
40	Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance). <i>Journal of Clinical Oncology</i> , 2016, 34, 3047-3053.	1.6	51
41	Subgroups of chemotherapy patients with distinct morning and evening fatigue trajectories. <i>Supportive Care in Cancer</i> , 2016, 24, 1473-1485.	2.2	42
42	TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON. <i>Radiology</i> , 2016, 279, 630-640.	7.3	109
43	Gene Expression Profiling of Evening Fatigue in Women Undergoing Chemotherapy for Breast Cancer. <i>Biological Research for Nursing</i> , 2016, 18, 370-385.	1.9	28
44	Impact of primary (1 st) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance). <i>Journal of Clinical Oncology</i> , 2016, 34, 3504-3504.	1.6	249
45	On the Verge: Immunotherapy for Colorectal Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 970-978.	4.9	9
46	Generalizability of Trial Results to Elderly Medicare Patients With Advanced Solid Tumors (Alliance) Tj ETQq0 0 0 rgBTj/Overlock 10 Tf 50	6.3	27
47	Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600E Mutant Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 4023-4031.	1.6	430
48	Sugar-Sweetened Beverage Intake and Cancer Recurrence and Survival in CALGB 89803 (Alliance). <i>PLoS ONE</i> , 2014, 9, e99816.	2.5	65
49	Colorectal Cancer: All Hands on Deck. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , 83-89.	3.8	9
50	25-Hydroxyvitamin D Levels and Survival in Advanced Pancreatic Cancer: Findings From CALGB 80303 (Alliance). <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	28
51	A case series of patients with HER2-overexpressed primary metastatic gastroesophageal adenocarcinoma. <i>Anticancer Research</i> , 2014, 34, 7357-60.	1.1	7
52	Impact of Physical Activity After Cancer Diagnosis on Survival in Patients With Recurrent Colon Cancer: Findings From CALGB 89803/Alliance. <i>Clinical Colorectal Cancer</i> , 2013, 12, 233-238.	2.3	31
53	Comparison of Dietary and Lifestyle Habits Among Stage III and Metastatic Colorectal Cancer Patients: Findings from CALGB 89803 and CALGB 80405. <i>Clinical Colorectal Cancer</i> , 2013, 12, 95-102.	2.3	17
54	Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance). <i>Clinical Cancer Research</i> , 2013, 19, 6957-6966.	7.0	95

#	ARTICLE	IF	CITATIONS
55	Dietary Glycemic Load and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings From CALGB 89803. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1702-1711.	6.3	163
56	Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma. <i>Cancer</i> , 2005, 103, 2435-2446.	4.1	72
57	Cancer and Leukemia Group B/Southwest Oncology Group Trial 80405: A Phase III Trial of Chemotherapy and Biologics for Patients with Untreated Advanced Colorectal Adenocarcinoma. <i>Clinical Colorectal Cancer</i> , 2005, 5, 292-294.	2.3	27
58	Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2004, 2 Suppl 2, S74-84.	4.9	0
59	Colorectal metastases confined to the liver: a unique opportunity?. <i>Seminars in Oncology</i> , 2003, 30, 34-39.	2.2	4
60	Therapeutic approaches to metastasis confined to the liver. <i>Current Oncology Reports</i> , 2001, 3, 109-115.	4.0	11
61	Phase I and Pharmacokinetic Trial of Gemcitabine in Patients With Hepatic or Renal Dysfunction: Cancer and Leukemia Group B 9565. <i>Journal of Clinical Oncology</i> , 2000, 18, 2780-2787.	1.6	177
62	Liver transplantation for hepatocellular carcinoma: Results with preoperative chemoembolization. <i>Liver Transplantation</i> , 1995, 1, 242-248.	1.8	70
63	Initiation of warfarin therapy. <i>Journal of General Internal Medicine</i> , 1987, 2, 141-148.	2.6	94